58 completed, 19 terminated, 14 unknown, 6 withdrawn. 106 Phase 2, 24 Phase 1, 4 Phase 3.
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 44 | 2026-02-12 | 2026-10-27 |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant Belumosudil - Graft Versus Host Disease, Graft Vs Host Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2025-05-21 | 2026-06-29 |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP) - Graft Versus Host Disease | Phase 2 | Withdrawn | Molly Gallogly | 2024-10-01 | 2025-01-07 | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine - Graft Versus Host Disease, Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 82 | 2024-07-18 | 2026-01-26 |
| Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment Wharton's jelly mesenchymal stem cells (WJ-MSCs) - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | 10 | 2024-06-01 | 2024-03-12 |
| Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT Cyclophosphamide - Graft Versus Host Disease | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 35 | 2023-01-01 | 2026-01-06 |
| A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD) VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | ViGenCell Inc. | 12 | 2022-11-20 | 2022-03-11 |
| Intestinal Microbiome-based Research for the Prevention of Acute GVHD sodium butyrate - Graft Versus Host Disease, Postbiotics | Phase 2 | Unknown | Soonchunhyang University Hospital | 15 | 2022-09-02 | 2023-04-12 |
| Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant Abatacept - Graft Versus Host Disease | Phase 2 | Active not recruiting | Emory University | 30 | 2019-08-22 | 2026-02-25 |
| Optimizing PTCy Dose and Timing Busulfan, Fludarabine, Cyclophosphamide - Graft Versus Host Disease, Hematologic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2019-07-09 | 2025-12-26 |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903 - Graft Versus Host Disease, Hematological Malignancies | Phase 1 / Phase 2 | Terminated | Centre Hospitalier Universitaire de Besancon | 2 | 2019-04-10 | 2025-07-09 |
| Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) Ruxolitinib 1.5% cream, vehicle cream - Graft Versus Host Disease, JNS Kinase | Phase 2 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 | 2018-11-19 | 2022-07-12 |
| Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies Cyclophosphamide, ATG - Bone Marrow Transplant Complications, Graft Versus Host Disease | Phase 2 / Phase 3 | Recruiting | Hospital Israelita Albert Einstein | 50 | 2018-11-06 | 2019-02-01 |
| Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG) - Graft Versus Host Disease | Phase 2 | Unknown | Sheba Medical Center | 30 | 2018-09-06 | 2023-11-28 |
| Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC Fludarabine, Clofarabine, Full body irradiation - Graft Versus Host Disease | Phase 2 | Terminated | Nantes University Hospital | 47 | 2018-01-15 | 2022-07-15 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Busulfan, Cyclophosphamide, Fludarabine Phosphate - Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 38 | 2017-05-30 | 2024-01-09 |
| A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD GLASSIA, methylprednisolone or equivalent steroid, Albumin - Graft Versus Host Disease | Phase 2 / Phase 3 | Terminated | Baxalta now part of Shire | 1 | 2017-04-26 | 2021-01-13 |
| Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Efprezimod alfa, Methotrexate, Tacrolimus - Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation | Phase 2 | Completed | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 44 | 2016-09-19 | 2024-01-23 |
Showing 20 of 106. Sign in to see all of them.
Graft vs Host Disease (106) · Leukemia (36) · Myelodysplastic Syndromes (34) · Leukemia, Myeloid, Acute (30) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (30) · Leukemia, Lymphocytic, Chronic, B-Cell (26) · Leukemia, Myeloid, Accelerated Phase (26) · Leukemia, Myeloid, Chronic-Phase (23) · Lymphoma, Follicular (22) · Lymphoma, Mantle-Cell (22) · Lymphoma, Non-Hodgkin (22) · Myeloproliferative Disorders (21) · Hodgkin Disease (20) · Lymphoma (20) · Lymphoma, B-Cell, Marginal Zone (20)
Immune System Diseases (105) · Hemic and Lymphatic Diseases (57) · Hematologic Diseases (55) · Neoplasms (54) · Neoplasms by Histologic Type (46) · Bone Marrow Diseases (41) · Lymphatic Diseases (40) · Immunoproliferative Disorders (39) · Chronic Disease (38) · Disease Attributes (38) · Lymphoproliferative Disorders (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38) · Leukemia, Myeloid (37) · Leukemia, Lymphoid (35)
Tacrolimus (35) · Cyclophosphamide (24) · Methotrexate (24) · Busulfan (19) · Cyclosporine (19) · Antilymphocyte Serum (17) · Mycophenolic Acid (17) · Sirolimus (17) · Peripheral Blood Stem Cell Transplantation (16) · fludarabine phosphate (16) · Methylprednisolone (15) · Melphalan (13) · Radiotherapy (8) · Whole-Body Irradiation (8) · Rituximab (7)
Fred Hutchinson Cancer Center (16) · City of Hope Medical Center (5) · Dana-Farber Cancer Institute (5) · Roswell Park Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Memorial Sloan Kettering Cancer Center (3) · Nantes University Hospital (3) · Alliance for Clinical Trials in Oncology (2) · Astellas Pharma Inc (2) · Case Comprehensive Cancer Center (2) · Emory University (2) · Jonsson Comprehensive Cancer Center (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Rabin Medical Center (2)
United States (72) · France (8) · Israel (4) · Canada (2) · Italy (2) · Japan (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · China (1) · Mexico (1) · Pakistan (1) · South Korea (1)
Barbara Jean Bambach, MD (4) · Stephanie Lee (3) · Corey Cutler, MD, MPH (2) · H. Joachim Deeg, MD (2) · Moshe Yeshurun, MD (2) · Steven C. Goldstein, MD (2) · Amin Alousi, MD (1) · Andreza A Feitosa Ribeiro, PhD (1) · Ann E. Woolfrey, MD (1) · Ann Woolfrey, MD (1) · Arnon Nagler, MD (1) · Auayporn P. Nademanee, MD (1) · Brenda Sandmaier (1) · Brenda W. Cooper, MD (1)
PMID 17910637, PMID 18769450, PMID 19286996, PMID 19539216, PMID 21874061, PMID 22002488, PMID 24140121, PMID 26033282, PMID 26053664, PMID 26189353, PMID 26378033, PMID 28864814, PMID 28924018, PMID 29326124, PMID 31260802, PMID 32973350, PMID 34102349, PMID 34156440, PMID 34242388, PMID 35007144, PMID 36624161, PMID 37189240, PMID 37301631, PMID 37647633, PMID 39908565
P30CA015704 (7), P30CA033572 (3), P30CA036727 (2), P30CA043703 (2), U10CA031946 (2), 2009 (1), P01CA015396 (1), P01CA018029 (1), P01CA023766 (1), P01CA030206 (1), P01CA078902 (1), P30CA006973 (1), P30CA008748 (1), P30CA012197 (1), P30CA016056 (1)